458 related articles for article (PubMed ID: 22229123)
1. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.
Kwong PD; Mascola JR; Nabel GJ
Cold Spring Harb Perspect Med; 2011 Sep; 1(1):a007278. PubMed ID: 22229123
[TBL] [Abstract][Full Text] [Related]
2. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
3. Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development.
Malherbe DC; Wibmer CK; Nonyane M; Reed J; Sather DN; Spencer DA; Schuman JT; Guo B; Pandey S; Robins H; Park B; Fuller DH; Sacha JB; Moore PL; Hessell AJ; Haigwood NL
Front Immunol; 2020; 11():984. PubMed ID: 32582155
[TBL] [Abstract][Full Text] [Related]
4. The Neutralizing Antibody Response to the HIV-1 Env Protein.
Moore PL
Curr HIV Res; 2018; 16(1):21-28. PubMed ID: 29173180
[TBL] [Abstract][Full Text] [Related]
5. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?
Subbaraman H; Schanz M; Trkola A
Retrovirology; 2018 Jul; 15(1):52. PubMed ID: 30055627
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing antibodies and control of HIV: moves and countermoves.
Hessell AJ; Haigwood NL
Curr HIV/AIDS Rep; 2012 Mar; 9(1):64-72. PubMed ID: 22203469
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody.
Cheng C; Pancera M; Bossert A; Schmidt SD; Chen RE; Chen X; Druz A; Narpala S; Doria-Rose NA; McDermott AB; Kwong PD; Mascola JR
J Virol; 2015 Dec; 90(6):2740-55. PubMed ID: 26719262
[TBL] [Abstract][Full Text] [Related]
8. Toward an antibody-based HIV-1 vaccine.
Hoxie JA
Annu Rev Med; 2010; 61():135-52. PubMed ID: 19824826
[TBL] [Abstract][Full Text] [Related]
9. Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1).
Killick MA; Grant ML; Cerutti NM; Capovilla A; Papathanasopoulos MA
Vaccine; 2015 Nov; 33(46):6298-306. PubMed ID: 26432912
[TBL] [Abstract][Full Text] [Related]
10. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
Sadanand S; Suscovich TJ; Alter G
Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
[TBL] [Abstract][Full Text] [Related]
11. Eliciting neutralizing antibodies against the membrane proximal external region of HIV-1 Env by chimeric live attenuated influenza A virus vaccines.
Zang Y; Du D; Li N; Su W; Liu X; Zhang Y; Nie J; Wang Y; Kong W; Jiang C
Vaccine; 2015 Jul; 33(32):3859-64. PubMed ID: 26126669
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
[TBL] [Abstract][Full Text] [Related]
13. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.
Ahmed Y; Tian M; Gao Y
AIDS Res Ther; 2017 Sep; 14(1):50. PubMed ID: 28893278
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.
Sliepen K; Sanders RW
Expert Rev Vaccines; 2016; 15(3):349-65. PubMed ID: 26654478
[TBL] [Abstract][Full Text] [Related]
15. Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies.
Mabvakure BM; Scheepers C; Garrett N; Abdool Karim S; Williamson C; Morris L; Moore PL
J Virol; 2019 Mar; 93(6):. PubMed ID: 30567996
[TBL] [Abstract][Full Text] [Related]
16. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
van Gils MJ; Sanders RW
Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
[TBL] [Abstract][Full Text] [Related]
17. High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site.
Sundling C; Li Y; Huynh N; Poulsen C; Wilson R; O'Dell S; Feng Y; Mascola JR; Wyatt RT; Karlsson Hedestam GB
Sci Transl Med; 2012 Jul; 4(142):142ra96. PubMed ID: 22786681
[TBL] [Abstract][Full Text] [Related]
18. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.
Spearman P; Lally MA; Elizaga M; Montefiori D; Tomaras GD; McElrath MJ; Hural J; De Rosa SC; Sato A; Huang Y; Frey SE; Sato P; Donnelly J; Barnett S; Corey LJ;
J Infect Dis; 2011 Apr; 203(8):1165-73. PubMed ID: 21451004
[TBL] [Abstract][Full Text] [Related]
19. Two closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates.
Vaine M; Duenas-Decamp M; Peters P; Liu Q; Arthos J; Wang S; Clapham P; Lu S
J Virol; 2011 May; 85(10):4927-36. PubMed ID: 21411542
[TBL] [Abstract][Full Text] [Related]
20. Antibody responses to envelope glycoproteins in HIV-1 infection.
Burton DR; Mascola JR
Nat Immunol; 2015 Jun; 16(6):571-6. PubMed ID: 25988889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
